Two-year sustained weight loss and metabolic benefits with controlled-release Phentermine/Topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study

@inproceedings{Powell2012TwoyearSW,
  title={Two-year sustained weight loss and metabolic benefits with controlled-release Phentermine/Topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study},
  author={Alex Fritz Powell},
  year={2012}
}

Similar Papers

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 162 CITATIONS, ESTIMATED 30% COVERAGE

Obesity: Pathogenesis and emerging targets for drug development

VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

ANTI-OBESITY PHARMACOTHERAPY AND THE POTENTIAL FOR PREVENTING PROGRESSION FROM PREDIABETES TO TYPE 2 DIABETES.

  • Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • 2015
VIEW 7 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED

Liraglutide and obesity: a review of the data so far

  • Drug design, development and therapy
  • 2015
VIEW 9 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity

  • Journal of hypertension
  • 2014
VIEW 4 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2012
2019

CITATION STATISTICS

  • 22 Highly Influenced Citations

  • Averaged 11 Citations per year from 2017 through 2019